明德生物：拟现金收购武汉必凯尔救助用品100%股权

Core Viewpoint - The company announced a significant asset restructuring through a cash acquisition of 100% equity in Wuhan Bikaier Rescue Supplies Co., Ltd. from Bluefan Medical, which is expected to enhance its focus on critical care business and build a synergistic ecosystem [1] Group 1: Acquisition Details - The acquisition agreement was signed on December 29, 2025, and is currently in the planning stage [1] - The final transaction price will be determined based on the assessed value of the target assets [1] Group 2: Strategic Importance - This acquisition is a key strategic move for the company to concentrate on the critical care segment [1] - The transaction aims to create a collaborative ecosystem within the company's operations [1] Group 3: Uncertainties and Risks - The transaction faces uncertainties related to due diligence and approval processes [1] - Potential operational and integration risks may arise from the acquisition [1]